Plasma Fractionation Market Report 2025

This Plasma Fractionation report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The plasma fractionation market size has grown strongly in recent years. It will grow from $31.42 billion in 2024 to $34.44 billion in 2025 at a compound annual growth rate (CAGR) of 9.6%. The growth in the historic period can be attributed to growing prevalence of hemophilia and immunodeficiency disorders, increased aging population, rising demand for immunoglobulins, expansion of plasma collection centers, growing number of surgical procedures.

The plasma fractionation market size is expected to see rapid growth in the next few years. It will grow to $51.56 billion in 2029 at a compound annual growth rate (CAGR) of 10.6%. The growth in the forecast period can be attributed to rising global healthcare expenditure, growing applications of plasma-derived medicinal products, increasing investment in research and development, demand for plasma in the treatment of neurological disorders, expansion of plasma fractionation facilities. Major trends in the forecast period include development of new fractionation technologies, shift towards albumin and immunoglobulin therapies, rising demand for specialty plasma products, focus on pathogen inactivation technologies, strategic collaborations and partnerships in the plasma industry.

The anticipated increase in the number of chronic diseases is set to drive the growth of the plasma fractionation market. Chronic diseases, lasting one year or more and requiring ongoing medical attention, include conditions like heart disease, cancer, and diabetes. The treatment of chronic disease patients through plasma products not only reduces morbidity but also enhances the quality of life and proves to be cost-effective. A report by the National Library of Medicine projects a 99. 5% rise in individuals aged 50 years and older with one or more chronic illnesses by 2050, reaching 142. 66 million, up from 71. 522 million in 2020 in the United States. The surge in chronic disease cases across all age groups is expected to fuel the growth of the plasma fractionation market.

The increasing prevalence of hemophilia is poised to be a significant driver for the plasma fractionation market. Hemophilia, a rare genetic disorder affecting blood clotting, leads to prolonged bleeding episodes. Plasma fractionation is vital for producing clotting factors administered to individuals with hemophilia to facilitate blood coagulation. According to the World Federation of Hemophilia, approximately 20,000 people with hemophilia are born globally each year, with 7,000 having severe cases. In the current global male population of 3. 9 billion, there are an estimated 818,928 hemophilia patients. Thus, the growing prevalence of hemophilia is expected to propel the plasma fractionation market.

Major companies in the market are introducing new technologies, such as high-tech facility processes that convert donated human plasma into essential medicines while utilizing advanced technology to enhance efficiency and safety. For example, in March 2023, CSL Behring, a German-based company, opened a new $470 million plasma fractionation facility that employs cutting-edge technology to improve the efficiency and safety of plasma processing, ensuring the production of higher quality and more reliable medicines. This facility addresses the increasing demand for these critical medicines, making life-saving treatments more accessible to patients. With advanced automation and self-cleaning systems in place, the facility minimizes the risk of contamination and improves overall hygienic conditions, thereby enhancing patient safety.

Strategic investments in expanding manufacturing capabilities for plasma-derived therapies (PDTs) are a focus for major players in the industry. This involves allocating resources to develop and enhance facilities and processes for the production of specialized therapies derived from blood plasma. In April 2023, Takeda Pharmaceutical, a Japan-based biopharmaceutical company, invested ¥100 billion (approximately $755. 8 million) to construct a state-of-the-art plasma-derived therapy manufacturing facility in Osaka. With a commitment to environmental sustainability, Takeda aims to achieve net-zero greenhouse gas emissions in its operations by 2035.

In April 2022, Grifols S. A., a Spain-based pharmaceutical and chemical product manufacturing company, completed the acquisition of Biotest AG for $317. 03 million (EUR 318 million). Through this strategic move, Grifols aims to enhance the availability of plasma medicines, expand its product line, and strengthen its position as the largest private European network of plasma facilities with 87 locations. The acquisition is expected to drive revenue growth, profitability expansion, and accelerate the advancement of research and development projects.

Major companies operating in the plasma fractionation market include Baxter International Inc., Bio Products Laboratory Limited, Biotest AG, CSL Limited, Grifols S. A, ADMA Biologics Inc., Green Cross Corporation, Hualan Bioengineering Inc., Intas Pharmaceuticals Ltd., Japan Blood Products Organization, Kedrion S. P. A., Kamada Ltd., LFB Biomedicaments S. A. S, Octapharma AG, Sanquin Plasma Products B. V., Shanghai Raas Blood Products Co. Ltd., Takeda Pharmaceutical Company, Terumo BCT, China Biologic Products Holdings Inc., China National Biotec Group, Emergent BioSolutions Inc., Bharat Serum Vaccines Limited, Plasma Therapeutics, Prothya Biosolutions B. V., BioPharma Plasma LLC, BioLife Plasma Services LP.

North America was the largest region in the plasma fractionation market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the plasma fractionation market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the plasma fractionation market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

Plasma fractionation is the process of integrating manufacturing procedures to sequentially isolate crude fractions, which are then further refined into specific medicinal products.

The primary products in the plasma fractionation market include immunoglobulins, coagulation factors, albumin, and protease inhibitors. Immunoglobulins find application in treating a wide range of disorders, encompassing primary and secondary immune deficiencies, autoimmune diseases, and inflammatory conditions. Immunoglobulins (Ig) and antibodies, glycoproteins produced by plasma cells, play a crucial role in the immune system's recognition and neutralization of foreign objects such as pathogenic bacteria and viruses. These products have various applications in immunology, hematology, neurology, critical care, hemato-oncology, and rheumatology, with end users spanning hospitals and clinics, clinical research laboratories, and academic institutes.

The plasma fractionation market research report is one of a series of new reports that provides plasma fractionation market statistics, including plasma fractionation industry global market size, regional shares, competitors with an plasma fractionation market share, detailed plasma fractionation market segments, market trends and opportunities, and any further data you may need to thrive in the plasma fractionation industry. This plasma fractionation market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The plasma fractionation market includes revenues earned by entities by combining manufacturing steps to isolate, in a sequential and integrated manner. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.